文献速递肝肾功能剂量调整治疗药物监测与药物基因组学

间歇性高通量血液透析患者万古霉素初始给药方案更新

An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

该研究采用蒙特卡洛模拟方法,为接受慢性间歇性高通量血液透析(iHFHD)的患者设计更新版万古霉素初始给药方案,以符合2020年治疗药物监测(TDM)共识指南。模拟结果显示,按体重分层的三档方案(负荷量1500-2500 mg,维持量750-1250 mg)在模拟人群中AUC24达标概率为第1天74.7%、第8天70.8%,且超过目标范围的比例低于10%。

要点

  • 按体重分三档:50-69 kg负荷1500 mg/维持750 mg;70-89 kg负荷2000 mg/维持1000 mg;90-110 kg负荷2500 mg/维持1250 mg。
  • 方案为透析期间静脉输注,每周三次透析时给予维持剂量。
  • 模拟人群中位负荷剂量25.0 mg/kg,中位维持剂量12.5 mg/kg。

核心结论

  • 所提出的iHFHD患者万古霉素给药方案为初始治疗提供了更新且实用的方法,可通过早期TDM进一步优化。

研究设计与样本

  • 采用蒙特卡洛模拟方法研究iHFHD患者的万古霉素给药方案。
  • 模拟人群样本量为n=5000。
  • 方案构建为透析期间静脉输注负荷剂量和后续透析时每周三次维持剂量。

主要发现

  • 模拟人群中位(IQR)负荷剂量为25.0(23.4-26.6)mg/kg,中位维持剂量为12.5(11.8-13.3)mg/kg。
  • AUC24 400-700 mg·h/L的达标概率第1天为74.7%,第8天为70.8%。
  • 超过目标范围的值低于10%。

关键数值与推荐

  • 体重50-69 kg:负荷1500 mg,维持750 mg。
  • 体重70-89 kg:负荷2000 mg,维持1000 mg。
  • 体重90-110 kg:负荷2500 mg,维持1250 mg。
  • 目标AUC24范围为400-700 mg·h/L。

临床怎么用

  • 对于iHFHD患者,可根据体重选择相应负荷和维持剂量起始万古霉素治疗。
  • 建议在治疗早期进行TDM以优化剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To design an updated vancomycin dosing protocol for initiating therapy in patients undergoing chronic intermittent high-flux hemodialysis (iHFHD) that is congruent with the revised 2020 consensus guidelines for therapeutic drug monitoring (TDM). METHODS: Monte Carlo simulation methods were used to study vancomycin dosing for patients on iHFHD. Vancomycin regimens were constructed as intravenous infusions (for intradialytic administration) of a loading dose and maintenance doses 3 times weekly during subsequent dialysis sessions. Vancomycin plasma concentrations were simulated, and the probability of target attainment (PTA) for a 24-hour area under the time-concentration curve (AUC24) of 400 to 700 mg · h/L was determined. Standardized weight-based (ie, dose-banding) regimens were investigated, and an optimized protocol was selected based on TDM target attainment and practical considerations for use in the dialysis setting. RESULTS: The proposed vancomycin dosing protocol (for intradialytic administration) specifies 3 regimens: (1) a 1,500-mg loading dose and 750-mg maintenance doses for patients weighing 50 kg to 69 kg; (2) a 2,000-mg loading dose and 1,000-mg maintenance doses for patients weighing 70 kg to 89 kg; and (3) a 2,500-mg loading dose and 1,250-mg maintenance doses for patients weighing 90 kg to 110 kg. In a simulated hemodialysis population (n = 5,000), the proposed protocol delivered median (interquartile range [IQR]) loading and maintenance doses of 25.0 (23.4-26.6) mg/kg and 12.5 (11.8-13.3) mg/kg, respectively. The PTA for an AUC24 of 400 to 700 mg · h/L was 74.7% on day 1 and 70.8% on day 8, with less than 10% of values exceeding the target range. CONCLUSION: Our proposed dosing protocol for patients undergoing iHFHD offers an updated and practical approach for initiating vancomycin therapy that can be optimized with early TDM.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Zelenitsky SA, Ariano RE. An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis. Am J Health Syst Pharm. 2022. PMID: 35234825. doi:10.1093/ajhp/zxac066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。